Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro

Leukemia volume 19, pages 1483–1485 (2005)Cite this article

TO THE EDITOR

The selective tyrosine kinase inhibitor imatinib has been shown to inhibit the Abl tyrosine kinases Bcr-Abl, c-Abl, v-Abl and Abl-related gene (ARG) as well as platelet-derived growth factor receptor (PDGF)-R alpha and beta and the receptor for human stem cell factor (SCF), c-kit.1 Side effects are mostly moderate; however, a dose-dependent hematologic toxicity affecting all hematopoietic lineages is observed clinically.2, 3 Based on the known functions of c-Abl, c-kit and PDGF-R in the hematopoietic system, one could speculate on potential hematotoxic side effects particularly after long-term exposure to the drug. In a recent study, we have shown that imatinib affected the proliferation of growth factor stimulated hematopoietic progenitor cells in vitro in a dose-dependent manner. The antiproliferative effect of imatinib was substantially greater, as compared to the withdrawal of stem cell factor or functional inhibition of c-kit at all dose levels tested. These data suggest a significant inhibitory effect of imatinib on normal CD34+ progenitor cells that is largely independent of c-kit signaling.4 Based on this finding, the aim of this study was to investigate the molecular effects of imatinib and c-kit inhibition on the gene expression profile of normal human CD34+ cells in vitro.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–104.

    CAS  PubMed  Google Scholar 

  2. Druker BJ . Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003; 40: 50–58.

    Article  CAS  Google Scholar 

  3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al., The IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  Google Scholar 

  4. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buehring HJ et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523–529.

    Article  CAS  Google Scholar 

  5. Brummendorf TH, Dragowska W, Zijlmans JMJM, Thornbury G, Lansdorp PM . Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells. J Exp Med 1998; 188: 1117–1124.

    Article  CAS  Google Scholar 

  6. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP . Characterization of gene expression of Cd34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553–3560.

    Article  CAS  Google Scholar 

  7. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L et al. Cyclin G2 associates with protein phosphatase 2a catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem 2002; 277: 27449–27467.

    Article  CAS  Google Scholar 

  8. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW et al. Cyclin G2 is up-regulated during growth inhibition and b cell antigen receptor-mediated cell cycle arrest. J Biol Chem 1997; 272: 12650–12661.

    Article  CAS  Google Scholar 

  9. Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B et al. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005; 19: 458–460.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. S Balabanov and K Bartolovic: Both these authors contributed equally

Authors and Affiliations

  1. Department of Hematology, Oncology and Immunology, University Medical Center, Tübingen, Germany

    S Balabanov, K Bartolovic, L Kanz & T H Brümmendorf

  2. Department of Hematology and Oncology, University Medical Center, Frankfurt/Main, Germany

    M Komor & W K Hofmann

Authors
  1. S Balabanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Bartolovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Komor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W K Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T H Brümmendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T H Brümmendorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balabanov, S., Bartolovic, K., Komor, M. et al. Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro. Leukemia 19, 1483–1485 (2005). https://doi.org/10.1038/sj.leu.2403819

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403819

Search

Advanced search

Quick links